Koers Corbus Pharmaceuticals Holdings, Inc.
Aandelen
CRBP
US21833P3010
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
37,35 USD | +0,84% | +5,09% | +518,38% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 391 mln. 365 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -53 mln. -49,47 mln. | Nettowinst (verlies) 2025 * | -65 mln. -60,67 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-7,16
x | K/w-verhouding 2025 * |
-7,28
x | Werknemers | 19 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,31% |
Recentste transcriptie over Corbus Pharmaceuticals Holdings, Inc.
1 dag | +0,84% | ||
1 week | +5,09% | ||
Lopende maand | +0,84% | ||
1 maand | -1,68% | ||
3 maanden | +34,40% | ||
6 maanden | +639,60% | ||
Lopend jaar | +518,38% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 01-07-13 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 11-04-14 |
Chief Tech/Sci/R&D Officer | 50 | 28/02 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 01-01-14 |
Avery Catlin
BRD | Director/Board Member | 75 | 01-08-14 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 01-07-13 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
01-05-24 | 37,25 | +0,57% | 133 291 |
30-04-24 | 37,04 | +3,93% | 197 603 |
29-04-24 | 35,64 | +4,06% | 92 849 |
26-04-24 | 34,25 | +2,24% | 96 876 |
25-04-24 | 33,5 | -5,74% | 142 333 |
uitgestelde koers Nasdaq, 01 mei 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+518,38% | 389 mln. | |
-1,17% | 102 mld. | |
+2,87% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-14,77% | 21,4 mld. | |
-8,79% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-13,21% | 16,09 mld. | |
+8,55% | 13,83 mld. | |
+35,75% | 11,97 mld. |